Last updated on: (28/04/24)

Site Info	
Site Name	Advanced Centre for Treatment, Research and Education in Cancer
Address	Sector 22, Utsav Chowk - CISF Rd, Owe Camp, Kharghar, Navi Mumbai, Maharashtra 410210

Experience and Available Capacity	
Infrastructure	The Advanced Centre for Treatment, Research and Education in Cancer (ACTREC) is the state-of-the-art R&D wing of the Tata Memorial Centre. ACTREC comprises the Cancer Research Institute (CRI), Clinical Research Centre (CRC) and Centre for Cancer Epidemiology (CCE), a setting that is unique in India and built and evolved with a vision to provide comprehensive cancer care to one and all. ACTREC can serve cancer patients with a capacity of 900 beds. The projects are technologically and thematically complex, including a Proton Beam Therapy Centre, a Centre to treat children's and hematological cancers, a Centre to treat solid tumors, and an advanced centre for nuclear medicine. The clinical pharmacology department in ACTREC focuses on the early phases of drug development and has been undertaking phase I clinical trials for more than 15 years. Phase I unit has the SOPs for undertaking the phase I clinical trials. The phase I unit has the latest equipment for the phase I clinical trials. The research team is experienced in handling Phase I clinical trials. The phase I unit is well supported by the clinical colleagues in the hospital who handle medical or surgical emergencies. Patient management is well supported by the presence of NABL accredited laboratory, which runs 24/7. In addition, ACTREC also handles patient emergencies with fully functional casualty and 16- independent ICU bedded facilities. In addition, the phase I unit is well supported by the hospital's nursing team, as well as research nurse availability. The Clinical Pharmacology Phase I unit has an independent research pharmacy. Radiology services (CT, PET, and MRI) are equipped with the latest and most advanced machines to support clinical research and hospital services. In addition, the department also has a well-established bioanalytical facility equipped with HPLCs and LCMSMS. Recently, High-resolution mass spectrometry was procured from the ICMR Centre for Advanced Research Project to undertake metabolomics analyses.

Sl.No.	Name	Designation	Role
1	Dr. Vikram Gota	Professor, Clinical Pharmacology	Officer in charge; Co-Investigator
2	Dr. Manjunath Nookala Krishnamurthy	Assoc. Professor, Clinical Pharmacology, ACTREC	Principal Investigator – ICMR CAR Phase I unit
3	Dr Anbarasan Sekar	Assoc. Professor, Medical Oncology, ACTREC	Principal Investigator –ICMR / AUR 107 Trial
4	Dr. Jaya Ghosh	Professor, Medical Oncology, ACTREC	Co-Investigator
5	Mrs. Sadhana Kannan	Officer in charge, Biostatistics department	Undertaking data analysis
6	Ms. Chital Naresh	Officer in charge, Quality control department, ACTREC	Quality control of all the labs in ACTREC

Sl. No.	Co-Investigators (ACTREC)
1	Dr. Sudeep Gupta
2	Dr. Amit Joshi
3	Dr. Kumar Prabhash
4	Dr. Sushmita Rath
5	Dr. Pallavi Parab
6	Dr. Vanita Noronha
7	Dr. Nandini Menon
8	Dr. Vikas Oswal
9	Dr. Navin Khattry
10	Dr. Sachin Punatar
11	Dr. Anant Gokarn
12	Dr. Summet Mirgh
13	Dr. Nishant Jindal

14	Dr. Chaitali Nashikkar

Sl. No	**Project Staff**
1	Project research Scientist II–Medical -Dr Joe Joseph
2	Project research Scientist I – (NM) -Mr Ganesh Chepuri -Mrs Akshata Patil
3	Project research Scientist I (Bio Analysis)–(NM) Mrs Shraddha Jadhav
4	Research nurse -Mrs Shraddha Patil
5	Pharmacometrician -Dr Aswathy VS

Early phase trial info:						
Year of start	**Title**	**Therapeutic Area**	**Status**	**PI**	**Regulatory/ Academic**	**CTRI Number**
ICMR Sponsored/co-sponsored trials						
2025	A Phase 1, Open Label, Dose Escalation, Dose Expansion, Multicentre, First in Human (FIH) Study Evaluating the Safety, Pharmacokinetics and Pharmacodynamics of Oral AUR107 in Patients with Relapsed Advanced Malignancies (SHAKTI-1)	All advanced solid tumors and multiple myeloma	Ongoing	Dr. Anbarasan Sekar	Regulatory	CTRI/2023/05/052954
Other trials						

2014	A Phase I Clinical Study to evaluate the safety, pharmacokinetics and anti-tumor activity of NRC-2694-A in patients with advanced Solid Malignancies.	All Advanced solid tumors	Completed	Dr. Kumar Prabhash	Regulatory	CTRI/2014/01/004293
2017	Phase I Clinical trial of an oral therapeutic agent Bioplatin in patients with solid tumours refractory to conventional therapies and advanced metastatic tumours.	All Advanced solid tumors	Completed	Dr. Vikram Gota	Regulatory	CTRI/2017/06/008778
2022	A Single Ascending Dose, Phase I Trial to Assess Safety, Tolerability and Pharmacokinetic Profile of MSP008-22 in Patients with Advanced Solid Tumours	All Advanced solid tumors	Ongoing	Dr. Manjunath Nookala Krishnamurthy	Regulatory	CTRI/2022/06/043504
2017	A phase I study to determine Safety, Tolerability, Pharmacokinetics, and activity of K0706, a Novel tyrosine Kinase (TKI), in subjects with Chronic Myeloid Leukemia (CML) or Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia (Ph+ALL).	Acute lymphoblastic leukemia	Ongoing	Dr. Navin Khattry	Regulatory	CTRI/2017/03/008178
2021	Phase I study to evaluate the feasibility and safety of addition of ruxolitinib to a standard BFM-90 regimen in adolescent/adult Ph-like ALL.	Acute lymphoblastic leukemia	Ongoing	Dr. Hasmukh Jain	Academic	CTRI/2021/02/031251

Certifications/Accreditations/Audits	The Clinical Pharmacology department successfully underwent an FDA inspection from March 19 to March 23, 2018, regarding a bioequivalence clinical trial conducted for the pharmaceutical industry
Point of Contact	**Name**: Dr. Manjunath Nookala Krishnamurthy **Email**: nk.manjunath@gmail.com **Phone**: +91 22 68735000; 8200